Jill Gilmour is the Executive Director for Human Immunology at the International AIDS Vaccine Initiative (IAVI) and Principal Investigator of the IAVI Human Immunology Laboratory (HIL) at Imperial College London. With more than 20 years of experience in HIV research and development, focusing on the African epidemic, she is responsible for IAVI’s Clinical Laboratory Program and staff internationally, overseeing research strategy, immune monitoring, data, quality, and scientific and laboratory capacity building to support HIV vaccine trials and epidemiology studies. Dr Gilmour is also the founding member and Director of the HIL, leading a team of 40. Dr Gilmour engages with a broad spectrum of International Donors, participates in many international steering and working groups, and is the PI/co-investigator on a number of grants and awards to support assay validation, reference testing and training for global consortia and vaccine initiatives, including PATH-MVI, WHO-Ebola, Wellcome Trust UK-HIV Vaccine Consortia, CAVD-VIMC and the European HIV Vaccine Alliance and the European AIDS Vaccine Initiative, two consortia of the European Union’s Horizon 2020 health program.
Dr Gilmour has overseen IAVI’s laboratory capacity-building program from site selection through the full accreditation of 12 laboratories across Africa and India, and has developed and co-lead multi-center immunology and epidemiology studies in East and Southern Africa. She is a founder and IAVI Scientific Director for the VISTA Initiative (Vaccine Immunology Science and Technology for Africa), developing strategic partnerships to encourage collaboration, technology transfer and training opportunities with partners in Europe, the United States, Africa and India.
Prior to joining IAVI in 2001, Dr Gilmour’s research focused on the host immune system in HIV transmission notably in the African epidemic. She held a post-doctoral fellowship of the UK MRC AIDS directed program and was a Lecturer at Imperial College London, and worked with MRC/UVRI Uganda Research Unit on AIDS to develop its cellular immunology laboratory, mentoring Ph.D. students and technical staff based in the United Kingdom and Uganda. She has co-authored more than 100 peer-reviewed scientific publications and holds a Hon Readership in Vaccine Immunology at Imperial College London. Dr Gilmour obtained her Honors Degree and Ph.D. from the University of Edinburgh.
et al., 2019, Reduced frequency of HIV superinfection in a high-risk cohort in Zambia, Virology, Vol:535, ISSN:0042-6822, Pages:11-19
et al., 2019, Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection, Journal of Infectious Diseases, Vol:220, ISSN:0022-1899, Pages:432-441
et al., 2019, Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial, Lancet Hiv, Vol:6, ISSN:2352-3018, Pages:E230-E239
et al., 2019, Induction and maintenance of bi-functional (IFN-gamma(+) IL-2(+) and IL-2(+) TNF-alpha(+))T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India, Plos One, Vol:14, ISSN:1932-6203
et al., 2019, Effect of incident hepatitis C infection on CD4(+) cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort, Aids, Vol:33, ISSN:0269-9370, Pages:327-337